Abeona Therapeutics (NASDAQ: ABEO) recently received a number of ratings updates from brokerages and research firms:

  • 10/16/2017 – Abeona Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock, up previously from $20.00.
  • 10/11/2017 – Abeona Therapeutics had its price target raised by analysts at Cantor Fitzgerald from $21.00 to $34.00. They now have an “overweight” rating on the stock.
  • 10/10/2017 – Abeona Therapeutics is now covered by analysts at Citigroup Inc.. They set a “buy” rating and a $32.00 price target on the stock.
  • 10/9/2017 – Abeona Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock, up previously from $20.00.
  • 10/6/2017 – Abeona Therapeutics had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $21.00 price target on the stock.
  • 9/18/2017 – Abeona Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
  • 9/14/2017 – Abeona Therapeutics is now covered by analysts at Royal Bank Of Canada. They set an “outperform” rating and a $23.00 price target on the stock.
  • 9/8/2017 – Abeona Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
  • 8/29/2017 – Abeona Therapeutics was given a new $17.00 price target on by analysts at Maxim Group. They now have a “buy” rating on the stock.

Abeona Therapeutics Inc. (ABEO) opened at 17.85 on Wednesday. The firm’s market cap is $719.12 million. The firm has a 50-day moving average of $16.44 and a 200 day moving average of $9.42. Abeona Therapeutics Inc. has a 1-year low of $4.05 and a 1-year high of $22.75.

Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings results on Tuesday, August 15th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.07). Abeona Therapeutics had a negative net margin of 2,746.38% and a negative return on equity of 26.66%. The firm had revenue of $0.22 million for the quarter, compared to analyst estimates of $0.21 million. On average, analysts predict that Abeona Therapeutics Inc. will post ($0.70) EPS for the current year.

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Receive News & Ratings for Abeona Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.